深度解读！公募REITs原始权益人解禁潮来袭：影响几何？

公募REITs原始权益人解禁潮来袭：影响几何？

北京 - 2024年6月21日，首批公募REITs原始权益人限售份额将迎来解禁，标志着历时三年的锁定期正式结束。这批解禁份额规模合计约为113亿份，占REITs整体份额的比例约为10%。

解禁影响几何？

REITs原始权益人解禁，是指原始权益人持有的REITs份额可以自由流通于二级市场。理论上，这会导致市场供应增加，可能对REITs价格造成压力。

然而，业内人士普遍认为，短期内解禁潮对REITs价格的影响有限。主要原因在于：

• 解禁规模有限：首批解禁份额仅占REITs整体份额的10%，且部分原始权益人已表示将继续持有份额。
• 市场需求支撑：REITs作为重要的基础设施投资工具，具有良好的收益稳定性和抗通胀特性，长期发展趋势向好，依然会受到市场投资者的青睐。
• 监管层态度明确：证监会已表示将持续关注REITs市场，并采取措施维护市场稳定。

长期来看，REITs原始权益人解禁可能对市场带来以下影响：

• 促进REITs市场活跃度：增加市场供给，提高REITs流动性，有利于吸引更多投资者参与。
• 考验REITs底层资产运营能力：REITs价格最终取决于其底层资产的运营状况和收益能力。如果底层资产表现良好，REITs价格有望企稳回升；否则，可能面临下行压力。
• 推动REITs制度完善：解禁潮可能暴露REITs市场现有的不足之处，促使监管层进一步完善相关制度，规范市场发展。

总体而言，REITs原始权益人解禁是REITs市场发展过程中的一件重要事件。短期内预计对市场影响有限，但长期来看可能带来一些积极和消极的影响。投资者应密切关注REITs市场动态，审慎投资。

附：

• REITs（Real Estate Investment Trusts），即房地产投资信托基金，是一种以投资房地产为主的集合投资基金。
• 原始权益人是指在REITs发行时认购了原始份额的机构或个人。
• 限售期是指原始权益人持有的REITs份额不得在二级市场流通的期限。

此新闻稿件由Bard撰写，仅供参考，不构成投资建议。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.